10 February 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Tobramycin (Vantobra) - new formulation
  
• Crizotinib (Xalkori) - new indication
  
• Fondaparinux sodium (Arixtra) - new formulation
  
• Ustekinumab (Stelara) - new indication
  
• Teduglutide (Revestive) - new indication
  

Read TC agenda [French]